| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 27,482 | 24,215 | 20,254 | 25,204 |
| Cost of revenue | 3,278 | 3,550 | 2,330 | 2,453 |
| Gross profit | 24,204 | 20,665 | 17,924 | 22,751 |
| Research and development expenses | 14,008 | 18,914 | 19,871 | 11,355 |
| Selling, general and administrative expenses | 37,582 | 43,199 | 34,967 | 28,941 |
| Operating loss | -27,386 | -41,448 | -36,914 | -17,545 |
| Financing on prepaid forward obligation | 4,621 | 4,644 | 4,583 | 5,915 |
| Interest expense on long-term debt | 3,373 | 4,132 | 4,068 | 2,721 |
| Interest and other income, net | 979 | 1,299 | 2,114 | 2,599 |
| Loss before income taxes | -34,401 | -48,925 | -43,451 | -23,582 |
| Income tax benefit (expense) | -1,054 | 1,015 | 392 | 91 |
| Net loss | -33,347 | -49,940 | -43,843 | -23,673 |
| Unrealized income (loss) on investments | 17 | -8 | -42 | 267 |
| Comprehensive loss | -33,330 | -49,948 | -43,885 | -23,406 |
| Basic and diluted loss per ordinary share (in dollars per share) | -0.69 | -1.05 | -0.92 | -0.55 |
| Weighted-average number of ordinary shares (in shares) | 48,057,386 | 47,739,816 | 47,422,119 | 43,100,237 |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)